Cargando…

The infection risks of JAK inhibition

INTRODUCTION: Janus Kinase inhibitors (JAKi) have shown to be highly effective in the treatment of immune-mediated inflammatory diseases. As with all immunomodulatory therapies, careful assessment of any treatment-associated infection risk is essential to inform clinical decision-making. AREAS COVER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adas, Maryam A., Alveyn, Edward, Cook, Emma, Dey, Mrinalini, Galloway, James B, Bechman, Katie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8935945/ https://www.ncbi.nlm.nih.gov/pubmed/34860621 http://dx.doi.org/10.1080/1744666X.2022.2014323

Ejemplares similares

The safety of JAK-1 inhibitors
por: Clarke, Benjamin, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of Anti-Rheumatic Drugs and Pneumococcal Vaccine Immunogenicity in Inflammatory Arthritis
por: Nagra, Deepak, et al.
Publicado: (2023)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
por: Russell, Mark D, et al.
Publicado: (2023)

P15 JAKi of all trades
por: Watkins, Clara, et al.
Publicado: (2023)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a UK national cohort
por: Adas, Maryam A, et al.
Publicado: (2023)

Infection profile of immune-modulatory drugs used in autoimmune diseases: analysis of summary of product characteristic data
por: Dey, Mrinalini, et al.
Publicado: (2022)

The immunosuppressed traveler: infection risks with autoimmunity and immunosuppression, vaccinations, and general travel advice
por: Allen, Victoria, et al.
Publicado: (2020)

Real-world evidence for prehospital COVID-19 treatment in systemic autoimmune rheumatic disease
por: Bechman, Katie, et al.
Publicado: (2023)

OA12 Grimey granulomas of sarcoidosis
por: Nagra, Deepak, et al.
Publicado: (2023)

A systematic review and network meta-analysis of the safety of early interventional treatments in rheumatoid arthritis
por: Adas, Maryam A, et al.
Publicado: (2021)

Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY
por: Russell, Mark D, et al.
Publicado: (2022)

IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression
por: Tharmarajah, Emmanuel, et al.
Publicado: (2021)

Worse outcomes linked to ethnicity for early inflammatory arthritis in England and Wales: a national cohort study
por: Adas, Maryam A, et al.
Publicado: (2022)

A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis
por: Bechman, Katie, et al.
Publicado: (2020)

Diagnosing Camurati–Engelmann disease—the age of whole-exome sequencing
por: Nagra, Deepak, et al.
Publicado: (2022)

Basic Mechanisms of JAK Inhibition
por: Lin, Chung MA, et al.
Publicado: (2020)

Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Corrigendum to: Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register
por: Bechman, Katie, et al.
Publicado: (2020)

Mental health, fatigue and function are associated with increased risk of disease flare following TNF inhibitor tapering in patients with rheumatoid arthritis: an exploratory analysis of data from the Optimizing TNF Tapering in RA (OPTTIRA) trial
por: Bechman, Katie, et al.
Publicado: (2018)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

O21 A case of thromboembolic ischaemic cardiomyopathy and intracardiac thrombus in a patient with antiphospholipid syndrome
por: Alveyn, Edward, et al.
Publicado: (2021)

Data quality predicts care quality: findings from a national clinical audit
por: Yates, Mark, et al.
Publicado: (2020)

Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases
por: Fragoulis, George E, et al.
Publicado: (2022)

JAK3 inhibition: what potential for the future?
por: Legendre, Christophe
Publicado: (2013)

Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit
por: Russell, Mark D, et al.
Publicado: (2021)

Corrigendum to: Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit
por: Russell, Mark D, et al.
Publicado: (2021)

Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?
por: Mehta, Puja, et al.
Publicado: (2020)

An overview of JAK/STAT pathways and JAK inhibition in alopecia areata
por: Lensing, Maddison, et al.
Publicado: (2022)

Enhancement of Cetuximab-Induced Radiosensitization by JAK-1 Inhibition
por: Bonner, James A., et al.
Publicado: (2015)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
por: Dey, Mrinalini, et al.
Publicado: (2021)

Beverages in Rheumatoid Arthritis: What to Prefer or to Avoid
por: Dey, Mrinalini, et al.
Publicado: (2020)

JAK inhibitors and infections risk: focus on herpes zoster
por: Sunzini, Flavia, et al.
Publicado: (2020)

JAK inhibition as a new treatment strategy for patients with COVID-19
por: Huang, Jin, et al.
Publicado: (2022)

NK cell modulation by JAK inhibition
por: Schönberg, Kathrin, et al.
Publicado: (2015)

Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis
por: Biggioggero, Martina, et al.
Publicado: (2019)

The molecular basis of JAK/STAT inhibition by SOCS1
por: Liau, Nicholas P. D., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8l0tie0atpvfvpg8srnndsuq13